Itac 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a critical component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itac 200 is indicated for the treatment of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and other dermatophytic infections. The capsule formulation ensures adequate bioavailability and patient compliance. It is important to administer Itac 200 with food to enhance absorption. Dosage and duration of therapy should be individualized based on the type and severity of infection, patient response, and clinical judgment. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored periodically during therapy. Itac 200 may interact with several drugs metabolized by the cytochrome P450 system; therefore, concomitant use with certain medications should be avoided or closely monitored. Common adverse effects include gastrointestinal disturbances, headache, and rash. Itac 200 should be used under medical supervision to ensure safety and efficacy.